Avantor Inc. (AVTR) Stock Forecast & Price Target

Avantor is viewed positively because its turnaround is gaining traction, with both segments beating expectations and VWR returning to positive organic growth of 1.7% while BMP posted double-digit order growth and a 1.1x book-to-bill. The company’s improved guidance, reaffirmed free cash flow of $500M–$550M, and raised adjusted EPS range of $0.80–$0.83 suggest that self-help actions, better service levels, and stronger e-commerce execution are starting to offset prior share losses. In addition, gradually improving end markets, including firmer large-pharma and biotech demand plus healthier funding conditions, could amplify operating leverage as management works toward restoring growth and sustaining margins around 14.8%–15.3%.

Avantor is facing a weak fundamental setup because its end markets have not normalized despite years of waiting, leaving organic growth vulnerable if demand recovery is delayed again or fails to materialize. The company also risks continued share losses to Thermo Fisher, while its wet-lab-heavy exposure creates structural pressure if software and AI reduce future wet lab activity, making its growth profile look slower than bioprocess peers. Financially, 2Q26 organic revenue fell 0.4% to $1.692B, gross margin declined about 120 bps to 31.7%, adjusted EBITDA margin fell about 160 bps to 15.0%, and leverage remained elevated at 3.3x, underscoring limited margin and balance-sheet flexibility.